Queen Mary University of London: Multiple Sclerosis trials
The registry lists 10 Multiple Sclerosis studies with Queen Mary University of London as lead sponsor. 2 are open to participants now and 2 have results posted.
Phase 2 5Phase 3 1No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and Equity in the National Health Service (NHS) Care of Multiple SclerosisRecruitingNCT07111637Not applicable
- Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)RecruitingNCT05418010Phase 2
- Oral Cladribine B-cell StudyCompletedNCT06415864Results posted
- Raltegravir (Isentress) Pilot Study in Relapsing Multiple SclerosisCompletedNCT01767701Phase 2Results posted
- ADAs to AlemtuzumabCompletedNCT06310343
- Famciclovir in Multiple SclerosisStatus unknownNCT05283551Phase 2
- ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple SclerosisActive, not recruitingNCT04695080Phase 2/3
- Under and Over Rehabilitation StudyCompletedNCT04490044Not applicable
- Neurofilaments for NEDA Assessing in MSTerminatedNCT03250169
- Protective Role of Oxcarbazepine in Multiple SclerosisCompletedNCT02104661Phase 2